Zimmer Biomet Holdings Management

Management criteria checks 2/4

Zimmer Biomet Holdings' CEO is Ivan Tornos, appointed in Mar 2021, has a tenure of 3.17 years. total yearly compensation is $10.19M, comprised of 9.5% salary and 90.5% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth MX$55.11M. The average tenure of the management team and the board of directors is 4.3 years and 9.3 years respectively.

Key information

Ivan Tornos

Chief executive officer

US$10.2m

Total compensation

CEO salary percentage	9.5%
CEO tenure	3.2yrs
CEO ownership	0.01%
Management average tenure	4.3yrs
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ivan Tornos's remuneration changed compared to Zimmer Biomet Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$10m	US$969k	US$1b
Sep 30 2023	n/a	n/a	US$474m
Jun 30 2023	n/a	n/a	US$506m
Mar 31 2023	n/a	n/a	US$450m
Dec 31 2022	US$6m	US$823k	US$290m
Sep 30 2022	n/a	n/a	US$366m
Jun 30 2022	n/a	n/a	US$334m
Mar 31 2022	n/a	n/a	US$325m
Dec 31 2021	US$5m	US$731k	US$445m
Sep 30 2021	n/a	n/a	US$834m
Jun 30 2021	n/a	n/a	US$914m
Mar 31 2021	n/a	n/a	US$563m
Dec 31 2020	US$4m	US$730k	-US$11m
Sep 30 2020	n/a	n/a	-US$152m
Jun 30 2020	n/a	n/a	US$37m
Mar 31 2020	n/a	n/a	US$377m
Dec 31 2019	US$4m	US$700k	US$1b
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$359m
Mar 31 2019	n/a	n/a	-US$308m
Dec 31 2018	US$4m	US$113k	-US$379m

Compensation vs Market: Ivan's total compensation ($USD10.19M) is above average for companies of similar size in the MX market ($USD5.86M).

Compensation vs Earnings: Ivan's compensation has increased by more than 20% in the past year.

CEO

Ivan Tornos (48 yo)

3.2yrs

Tenure

US$10,191,476

Compensation

Mr. Ivan Tornos serves as Independent External Director at PHC Holdings Corporation since September 03, 2021. He joined PHC Holdings Corporation on September 03, 2021. Mr. Tornos serves as Chief Operating...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ivan Tornos	COO, President	3.2yrs	US$10.19m	0.013% $ 55.1m
Suketu Upadhyay	CFO and Executive VP of Finance	4.8yrs	US$10.38m	0.010% $ 42.8m
Chad Phipps	Senior VP	17yrs	US$2.87m	0.024% $ 101.4m
Sang Yi	President of Asia Pacific	8.9yrs	US$3.38m	0.0089% $ 37.5m
Wilfred van Zuilen	Group President of Europe	2.9yrs	US$3.42m	0.0035% $ 14.8m
Paul Stellato	VP, Controller & Chief Accounting Officer	2yrs	no data	0.00046% $ 1.9m
Nitin Goyal	Chief Science	2.9yrs	no data	no data
Zeeshan Tariq	Senior VP & Chief Information Officer	7.8yrs	no data	no data
Keri Mattox	SVP and Chief Communications & Administration Officer	4.3yrs	no data	no data
Zachary Weiner	Director of Investor Relations	no data	no data	no data
Angela Main	Senior VP	8.9yrs	no data	no data
Lori Winkler	Senior VP & Chief Human Resources Officer	3.3yrs	no data	0.0016% $ 6.9m

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: ZBH *'s management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ivan Tornos	COO, President	less than a year	US$10.19m	0.013% $ 55.1m
Christopher Begley	Independent Chairman of the Board	11.8yrs	US$378.84k	0.0017% $ 7.3m
Betsy Bernard	Independent Director	15.3yrs	US$340.26k	0.0026% $ 10.9m
Robert Hagemann	Independent Director	16.2yrs	US$358.20k	0.0019% $ 8.3m
Michael Michelson	Independent Director	9.3yrs	US$318.84k	0.0016% $ 7.0m
Arthur Higgins	Independent Director	17.3yrs	US$347.75k	0.0016% $ 7.0m
Louis Shapiro	Director	less than a year	no data	no data
Maria Hilado	Independent Director	5.8yrs	US$314.44k	0.00080% $ 3.4m
Michael Farrell	Independent Director	9.4yrs	US$344.10k	0.00097% $ 4.1m
Sreelakshmi Kolli	Independent Director	3.3yrs	US$382.35k	0.00049% $ 2.1m
Syed Jafry	Independent Director	5.8yrs	US$367.52k	0.0020% $ 8.4m

9.3yrs

Average Tenure

63yo

Average Age

Experienced Board: ZBH *'s board of directors are considered experienced (9.3 years average tenure).

Zimmer Biomet Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Independent Director recently bought Mex$1.9m worth of stock

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Insufficient new directors

Insufficient new directors

Recent updates

Zimmer Biomet Holdings, Inc. to Report Q1, 2024 Results on May 02, 2024

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Upcoming dividend of US$0.24 per share

Fourth quarter dividend of US$0.24 announced

Full year 2023 earnings released: EPS: US$4.91 (vs US$1.39 in FY 2022)

Fourth quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration (FDA) 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024

Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Zimmer Biomet Holdings, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Zimmer Biomet Holdings, Inc. Approves Cash Dividend for the Fourth Quarter of 2023, Payable on or About January 31, 2024

Third quarter 2023 earnings released: EPS: US$0.78 (vs US$0.93 in 3Q 2022)

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Upcoming dividend of US$0.24 per share at 0.8% yield

Independent Director recently bought Mex$1.9m worth of stock

Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend for Third Quarter of 2023, Payable on or about October 31, 2023

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Second quarter 2023 earnings released: EPS: US$1.01 (vs US$0.73 in 2Q 2022)

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year 2023

Zimmer Biomet Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.24 per share at 0.7% yield

Insufficient new directors

Insufficient new directors

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.11 (vs US$0.35 in 1Q 2022)

Upcoming dividend of US$0.24 per share at 0.8% yield

Full year 2022 earnings released: EPS: US$1.39 (vs US$2.13 in FY 2021)

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.39 (vs US$1.93 in FY 2021)

Zimmer Biomet Holdings, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Embody, Inc. for approximately $300 million.

Insufficient new directors

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022, Payable on or About January 31, 2023

Insufficient new directors

Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearance of Persona(R) Osseoti(R) Keel Tibia for Cementless Knee Replacement

Insufficient new directors

Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Third quarter 2022 earnings released: EPS: US$0.93 (vs US$0.70 in 3Q 2021)

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc. Receives FDA Clearance for Identity(TM) Shoulder System for Shoulder Replacement

Zimmer Biomet Holdings, Inc Approves Quarterly Cash Dividend, Payable on or About October 31, 2022

Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021)

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Upcoming dividend of US$0.24 per share

Now 20% undervalued after recent price drop

Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer

Zimmer Biomet Holdings, Inc. Approves Quarterly Dividend for Second Quarter of 2022, Payable on or About July 29, 2022

Zimmer Biomet Holdings, Inc. Debuts First-Of-Its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room

Now 20% undervalued

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$0.93 (vs US$0.95 in 1Q 2021)

Insufficient new directors

Extremity Medical, LLC Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings, Inc. and Zimmer, Inc

Zimmer Biomet Holdings, Inc. to Report Q1, 2022 Results on May 03, 2022

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 16, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Insufficient new directors

Group President of Asia Pacific recently sold Mex$7.4m worth of stock

Upcoming dividend of US$0.24 per share